# Early Fluid Resolution Association with Treatment Interval Maintenance at Week 48 in Patients Receiving Aflibercept 8 mg: Phase 3 PULSAR Trial

**Varun Chaudhary,[1] Javier Zarranz-Ventura,[2] Sergio Leal,[3] Tobias Machewitz,[4] Stefanie Hofer,[5]**
**Peter Morgan-Warren,[6] Scott Fitzpatrick,[7] Zoran Hasanbasic,[3] Xin Zhang,[3] on behalf of the PULSAR study investigators**

*[1]Hamilton Regional Eye Institute, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada*
*[2]Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain*
*[3]Bayer Consumer Care AG, Basel, Switzerland*
*[4]Bayer AG, Berlin, Germany*
*[5]Bayer Consumer Care AG, Vienna, Austria*
*[6]Bayer PLC, Berkshire, UK*
*[7]Bayer Consumer Care AG, Mississauga, ON, Canada*

*Presented at the American Academy of Ophthalmology (AAO) 2023 Congress, San Francisco, CA, USA, November 3–6, 2023*

# Disclosures


- **VC**: Receives grants from Allergan Inc., Bayer Healthcare, Novartis Pharma AG, and Roche; is a scientific advisor for Alcon Laboratories, Bayer Healthcare, Novartis Pharma AG, and Roche
    - **JZV**: Receives grants from AbbVie, Allergan Inc., Bayer, Novartis, and Roche; is a member of scientific advisory boards for AbbVie, Allergan Inc., Bayer, Novartis, and Roche; is a speaker for Alcon, Alimera Sciences, Allergan Inc., AbbVie, Bausch + Lomb, Bayer, Brill Pharma, D.O.R.C., Esteve, Novartis, Roche, Topcon Healthcare, and ZEISS. **PMW, SF, SL, SH, ZH**, and **XZ**: Employees of Bayer Consumer Care AG. **TM**: Employee of Bayer AG
- The PULSAR study was sponsored by Bayer AG (Leverkusen, Germany) and co-funded by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA). The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation
- Study disclosures: This study includes research conducted on human patients. Institutional Review Board approval was obtained prior to study initiation
- The results from the PULSAR study were previously presented at the EURETINA Congress, October 5–8, 2023
- Medical writing support, under the direction of the authors, was provided by ApotheCom and funded by Bayer Consumer Care AG (Basel, Switzerland), in accordance with Good Publication Practice (GPP) standards (*Ann Intern Med* 2022;175:1298–1304)

# PULSAR Study Design and Dosing Schedule

pulsar nAMD

**96-week, multicenter, randomized, double-masked study in patients with treatment-naïve nAMD**
**Randomized at baseline 1 (2q8) : 1 (8q12) : 1 (8q16)**

**Key secondary endpoint:** Proportion of patients without IRF and SRF in the central subfield

**Primary endpoint:** Mean change in BCVA (non-inferiority)

| | Day 1 | Wk 4 | Wk 8 | Wk 12 | Wk 16 | Wk 20 | Wk 24 | Wk 28 | Wk 32 | Wk 36 | Wk 40 | Wk 44 | Wk 48 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2q8 (n=336) | X | X | X | | X | o | X | o | X | o | X | o | X |
| 8q12 (n=335) | X | X | X | | o | X | o | o | X | o | o | X | o |
| 8q16 (n=338) | X | X | X | | o | o | X | o | o | o | X | o | o |

## DRM Criteria for Shortening Dosing Interval

- >5-letter loss in BCVA compared with Week 12, due to persistent or worsening nAMD

AND

- >25 µm increase in CST compared with Week 12, or new-onset foveal neovascularization, or foveal hemorrhage

## DRM in Year 1

- Intervals can only be shortened
- Multiple opportunities to shorten interval
- Minimum interval for all patients was Q8

**Week 16 and 20:** Patients on 8q12 and 8q16 meeting DRM criteria shortened to Q8

**Week 24:** Patients on 8q16 meeting DRM criteria shortened to Q12

**Week 32 and 44 for 8q12 and Week 40 for 8q16:** Treatment interval shortened by 4 weeks for patients meeting DRM criteria

Stippled boxes = initial treatment phase; X = active injection; o = sham injection. Note: Table does not reflect all dosing options once a patient's dosing interval is shortened.
**2q8**, aflibercept 2 mg every 8 weeks after 3 initial monthly injections; **8q12**, aflibercept 8 mg every 12 weeks after 3 initial monthly injections; **8q16**, aflibercept 8 mg every 16 weeks after 3 initial monthly injections; **BCVA**, best-corrected visual acuity; **CST**, central subfield thickness; **DRM**, dose regimen modification; **IRF**, intraretinal fluid; **nAMD**, neovascular age-related macular degeneration; **Q8**, every 8 weeks; **Q12**, every 12 weeks; **SRF**, subretinal fluid; **Wk**, week.

# 48-Week Visual and Anatomic Outcomes

pulsar nAMD

**Primary endpoint:**

**BCVA Change from BL (LS Means)[a]**




**BCVA Change from BL at Week 48 (LS means; ETDRS letters)**
**+7.0 2q8**
**+6.1 8q12**
**+5.9 8q16**

**Absolute CST (Observed Values)[b]**




**CST Change from BL at Week 48 (LS means;[a] µm)**
**–147 8q16**
**–147 8q12**
**–136 2q8**

[a]LS mean values (censoring data post-ICE); FAS: 2q8 n=336; 8q12 n=335; 8q16 n=338 (at BL). LS means were generated using MMRM, with baseline BCVA measurement as a covariate, treatment group (aflibercept 2q8, 8q12, 8q16), visit, and stratification variables (geographic region [Japan vs. Rest of World] and BL BCVA [<60 vs. ≥60]) as fixed factors, and interaction terms for BL and visit and for treatment and visit. [b]Observed values (censoring data post-ICEs); FAS: 2q8 n=336; 8q12 n=335; 8q16 n=338 (at BL).

**BL**, baseline; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **FAS**, full analysis set; **ICE**, intercurrent event; **LS**, least squares; **MRMM**, mixed model for repeated measures.

# Analysis of Early Fluid Resolution Associated with Dosing Interval

pulsar nAMD

**Objective:**

To evaluate if early fluid resolution during the initial treatment phase may serve as a biomarker to predict the likelihood of patients with nAMD achieving extended dosing intervals with aflibercept 8 mg

**Methods:**

The presence of fluid at Weeks 4, 8, and 12 was analyzed in patients who received intravitreal aflibercept injections, after 3 initial monthly injections. Patients were categorized depending on their fluid status up to Week 12. In this analysis, we focus on the aflibercept 8q16 treatment group

| | Day 1 | Week 4 | Week 8 | Week 12 |
|---|---|---|---|---|
| **Aflibercept 8q16** |  |  |  | |
| Patients who were fluid free at Week 4 | | Fluid free  | / | / |
| Patients who were fluid free at Weeks 4 and 8 | | Fluid free  | Fluid free  | / |
| Patients who were fluid free at Weeks 4, 8, and 12 | | Fluid free  | Fluid free  | Fluid free  |
| Patients who were never fluid free during the initial treatment phase | | Fluid presence  | Fluid presence  | Fluid presence  |

Fluid status was not assessed on Day 1. Fluid is defined as IRF and SRF in the central subfield. Fluid free is defined as absence of IRF and SRF in central subfield. / = patients who were either fluid free, not fluid free, or with unknown fluid status.

# Early Fluid Resolution: A Potential Biomarker

pulsar nAMD

## Time to a Fluid-Free Central Subfield




FAS, 2q8 n=336; 8q12 n=335; 8q16 n=338. Time to fluid-free central subfield is defined as the time of first injection until the time where a patient did not have any IRF or SRF in the central subfield for the first time (regardless of whether any retinal fluid was found again after that). [a]Time to fluid-free retina was analyzed using the Kaplan–Meier method, using the study visits (i.e., multiples of 4 weeks) and not the calendar time as unit.

# Patients Maintaining ≥Q12- and Q16-Week Dosing Intervals at Week 48 Based on Early Fluid Status: Aflibercept 8q16 Treatment Group

pulsar nAMD

## Fluid Free at Week 4 (n=182[a])




| FAS, LOCF (n=200) | BCVA (ETDRS letters) | CST (µm) |
|---|---|---|
| Baseline | 60.9 | 342 |
| Week 48 | 66.1 | 221 |

## Fluid Free at Weeks 4 and 8 (n=164[a])




| FAS, LOCF (n=179) | BCVA (ETDRS letters) | CST (µm) |
|---|---|---|
| Baseline | 61.3 | 335 |
| Week 48 | 67.1 | 219 |

## Fluid Free at Weeks 4, 8, and 12 (n=159[a])




| FAS, LOCF (n=172) | BCVA (ETDRS letters) | CST (µm) |
|---|---|---|
| Baseline | 61.5 | 336 |
| Week 48 | 67.2 | 219 |

## Patients Who Were Never Fluid Free During the Initial Treatment Phase (n=50[a])




| FAS, LOCF (n=52) | BCVA (ETDRS letters) | CST (µm) |
|---|---|---|
| Baseline | 57.6 | 432 |
| Week 48 | 62.1 | 249 |

[a]Patients completing Week 48. [b]Patients shortened based on DRM assessments at some point through Week 48. **LOCF**, last observation carried forward.

# Conclusions

pulsar nAMD

## Fluid Free at Week 4 (n=182[a])




## Patients who were Never Fluid Free During the Initial Treatment Phase (n=50[a])




- Approximately **80% of patients** who were **fluid free at Week 4 maintained a Q16 interval** until Week 48 compared with **66% of patients** who had **never been fluid free** during the initial treatment phase
- These results suggest that early fluid resolution during the initial treatment phase may serve as a biomarker to predict the likelihood of patients with nAMD achieving extended dosing intervals with aflibercept 8 mg

[a]Patients completing Week 48. [b]Patients shortened based on DRM assessments at some point through Week 48.